newsfilter
← Latest News
GlobeNewswire·

Serina Therapeutics to Present at the 38th Annual Roth Conference

  • Serina Therapeutics (NYSE: SER) announced CEO Steve Ledger will present at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026 at 11:30 a.m. PST.
  • A live webcast of the fireside chat will be available to registered attendees with an on-demand replay accessible for 90 days post-event.
  • Serina is a clinical-stage biotechnology company headquartered in Huntsville, Alabama, developing drug candidates for neurological diseases using its proprietary POZ Platform™.
  • The POZ Platform utilizes a synthetic poly(2-oxazoline) polymer to improve drug loading control, release precision, & safety profiles for small molecules, RNA therapeutics, & antibody-drug conjugates.
  • The company holds a non-exclusive license agreement with Pfizer, Inc. to utilize its POZ polymer technology for lipid nanoparticle (LNP) drug delivery formulations.
  • SER-252 (POZ-apomorphine) is an investigational therapy designed to provide continuous dopaminergic stimulation to reduce levodopa-related motor complications in Parkinson's disease.
  • Preclinical studies indicate SER-252 has the potential to deliver continuous dopaminergic stimulation without causing skin reactions.
  • The press release includes a cautionary statement regarding forward-looking statements & risks related to clinical trials, regulatory approval, & commercial success.
  • Inquiries can be directed to Stefan Riley via email or phone at (256) 327-9630.